Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2
Key facts
- Where
- Budapest VIII, Debrecen, Nyíregyháza és Pécs, MagyarországSee the 4 sites
- Phase
- 3. fázis
Where in Magyarország
- Semmelweis UniversityBudapest VIII, MagyarországNo longer taking part
- University of DebrecenDebrecen, MagyarországNo longer taking part
- Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi OktatokorhazNyíregyháza, MagyarországNo longer taking part
- University of PecsPécs, MagyarországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Celgene Corp.
- Trial code
- EU 2022-500861-29-00
- Record updated
- 2026. szeptember 9.
- Original description
To compare the progression-free survival (PFS) of CC-92480, carfilzomib and dexamethasone (480Kd) to that of carfilzomib and dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma (RRMM)Read full original descriptionShow less
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
To compare the progression-free survival (PFS) of CC-92480, carfilzomib and dexamethasone (480Kd) to that of carfilzomib and dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma (RRMM)
Inclusion: Participant has documented diagnosis of multiple myeloma (MM) and measurable disease, defined as any of the following: a. M-protein ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or b. M-protein ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) or, c. For participants without measurable disease in sPEP or uPEP: sFLC levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal κ/λ FLC ratio; Participant has received at least 1 prior line of anti-myeloma therapy; Participant must have received prior treatment with lenalidomide and an anti-CD38 monoclonal antibody. For country-specific requirements, refer to Appendix12; Participant achieved minimal response (MR) or better to at least 1 prior anti-myeloma therapy; Participant must have documented disease progression during or after their last anti-myeloma regimen; Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
Exclusion: Participant who has had prior treatment with mezigdomide or carfilzomib; Participant who has had any investigational agents within 28 days or 5 half-lives (whichever is shorter) of initiating study intervention; Participant has previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of initiating study intervention; Participant with known central nervous system (CNS) involvement with myeloma.